Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07005154 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
A Phase 2 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, sponsored by Astellas Pharma Global Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
- 12
- Study locations
NCT07005154: Recruiting Phase 2 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, sponsored by Astellas Pharma Global Development.
NCT07005154 is a Phase 2 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Astellas Pharma Global Development. The registered enrollment target is 218 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07005154, a Phase 2 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Astellas Pharma Global Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
- 12
- Study locations
Study Summary
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is made or block testosterone from reaching the prostate cancer cells. Abiraterone acetate (AA) is an ARPI that is used to treat advanced prostate cancer. This type of treatment is usually given as a tablet with a steroid called prednisone/prednisolone to manage any medical problems from the hormone therapy. ASP5541 is a different form of abiraterone acetate. It is given as an injection into the muscle. In this study, ASP5541 will be given to men with advanced prostate cancer, both with and without prednisone/prednisolone. This study will check the safety of ASP5541 and compare how well ASP5541 works in men with advanced prostate cancer compared to abiraterone acetate. The main aims of the study are: * To check how well ASP5541 with prednisone/prednisolone works compared to AA with prednisone/prednisolone in men with advanced prostate cancer who haven't previously been treated with an ARPI. * To check the safety of ASP5541 given by itself in men with advanced prostate cancer that haven't previously been treated with an ARPI. * To check how well ASP5541 given by itself works compared to AA with prednisone/prednisolone in men with advanced prostate cancer that haven't previously been treated with an ARPI. * To check the safety of ASP5541 with prednisone/prednisolone in Japanese men with advanced prostate cancer. Adult men with a certain type of advanced prostate cancer can take part. Their cancer has spread to other parts of the body (metastatic). The different types are: * Metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer that needs testosterone to grow. * Metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer that co
Primary Outcome
PSA will be recorded from blood sample.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG abiraterone acetate
- DRUG Prednisolone
- DRUG ASP5541
- DRUG Adrenocorticotropic hormone
Study Locations (12)
Other
- Harasanshin Hospital - Fukuoka
- Osaka International Cancer Institute - Osaka
- PanOncology Trials - San Juan
- KR82008 - Gwangju
Tokyo
- Nippon Medical School Hospital - Bunkyo-ku
- The Cancer Institute Hospital of JFCR - Koto-ku
Florida
- H. Lee Moffitt Cancer Center - Tampa
New Mexico
- New Mexico Oncology Hematology Consultants - Albuquerque
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Baden-Wurttemberg
- DE49004 - Nürtingen
Chiba
- National Cancer Center Hospital East - Kashiwa
Shizuoka
- Shizuoka Cancer Center - Sunto-gun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2032-05-31 |
| Phase | Phase 2 |
What NCT07005154 shows while recruiting
NCT07005154 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower).
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Prednisone is the first listed.
NCT07005154 lists 12 locations in 8 states (Other, Tokyo, Florida).
Frequently Asked Questions
What is clinical trial NCT07005154 about?
NCT07005154 is a clinical study titled "A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer". Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much ...
What is the current status of trial NCT07005154?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2025-06-19. Estimated completion is 2032-05-31.
What conditions does trial NCT07005154 study?
This clinical trial studies the following conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer.
What interventions are being tested in trial NCT07005154?
The interventions under investigation include: Prednisone (DRUG), abiraterone acetate (DRUG), Prednisolone (DRUG), ASP5541 (DRUG), Adrenocorticotropic hormone (DRUG).
Who is sponsoring clinical trial NCT07005154?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07005154 being conducted?
This trial has 12 study locations across Florida, New Mexico, South Carolina, Baden-Wurttemberg, Chiba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07005154's enrollment target sits among peer trials
218 212th of 735 higher than 524 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI